Innate Immunotherapeutics (English Wikipedia)

Virionyx Changes Name to Innate Therapeutics, Advances Novel Immune Stimulant, MIS416, to Clinical Trials, Auckland, New Zealand, April 17, 2009, retrieved January 24, 2017{{citation}}: CS1 maint: location missing publisher (link) Contact Joan E. Kureczka, Kureczka/Martin Associates, MSEM Founder and Principal and the Vivant Group, San Francisco, California

clinicaltrials.gov

"Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple Sclerosis". United States Library of Medicine (NIH). Clinical trials (NCT02228213). July 14, 2017. Retrieved August 8, 2018.

cnbc.com

Breuninger, Kevin (August 8, 2018). "New York GOP Rep. Chris Collins to be indicted on insider trading charges". CNBC. Retrieved August 8, 2018.

congress.gov

Bill 4848, US Congress, March 2016, retrieved January 24, 2017, introduced by Tom Price(R-GA-6) on March 23, 2016 to House Energy and Commerce Committees: House - Energy and Commerce; Ways and Means Latest Action:03/30/2016 Referred to the Subcommittee on Health on March 30, 2016

doi.org

Shirani, Afsaneh; Okuda, Darin T.; Stüve1, Olaf (January 2016). "Therapeutic Advances and Future Prospects in Progressive Forms of Multiple Sclerosis". Neurotherapeutics. 3 (1): 58–69. doi:10.1007/s13311-015-0409-z. PMC 4720678. PMID 26729332.{{cite journal}}: CS1 maint: numeric names: authors list (link)
96. Girvan RC, Knight DA, O'Loughlin CJ, Hayman CM, Hermans IF, Webster GA. MIS416, a non-toxic microparticle adjuvant derived from Propionibacterium acnes comprising immunostimulatory muramyl dipeptide and bacterial DNA promotes cross-priming and Th1 immunity. Vaccine. 2011;29:545–557. doi:10.1016/j.vaccine.2010.10.040
Madeleine, White; Webster, Gill; O'Sullivan, David; Stone, Sarrabeth; La Flamme, Anne Camille (January 31, 2014). "Targeting innate receptors with MIS416 reshapes Th responses and suppresses CNS disease in a mouse model of multiple sclerosis". PLOS ONE. 9 (1): e87712. Bibcode:2014PLoSO...987712W. doi:10.1371/journal.pone.0087712. PMC 3909208. PMID 24498172. [PMC free article] [PubMed] [Cross Ref]
Girvan RC, Knight DA, O'Loughlin CJ, Hayman CM, Hermans IF, Webster GA (January 10, 2011). "MIS416, a non-toxic microparticle adjuvant derived from Propionibacterium acnes comprising immunostimulatory muramyl dipeptide and bacterial DNA promotes cross-priming and Th1 immunity". Vaccine. 29 (3): 545–57. doi:10.1016/j.vaccine.2010.10.040. PMID 21034827.
Luckey, Alison M; Anderson, Tim; Silverman, Michael H; Webster, Gill (January 2015). "Safety, tolerability and pharmacodynamics of a novel immunomodulator, MIS416, in patients with chronic progressive multiple sclerosis". Multiple Sclerosis Journal: Experimental, Translational and Clinical. 1: 2055217315583385. doi:10.1177/2055217315583385. PMC 5433401. PMID 28607691.

harvard.edu

ui.adsabs.harvard.edu

Madeleine, White; Webster, Gill; O'Sullivan, David; Stone, Sarrabeth; La Flamme, Anne Camille (January 31, 2014). "Targeting innate receptors with MIS416 reshapes Th responses and suppresses CNS disease in a mouse model of multiple sclerosis". PLOS ONE. 9 (1): e87712. Bibcode:2014PLoSO...987712W. doi:10.1371/journal.pone.0087712. PMC 3909208. PMID 24498172. [PMC free article] [PubMed] [Cross Ref]

incresearch.com

"INC Research". INCR (NASDAQ)]. Raleigh, North Carolina. According to SEC filings, INCR CEO Alistair Macdonald, who established INC Research in October 1, 2016, holds $2,669,127 in company stocks after selling shares worth $69,437.50 on January 20, 2017.(NASDAQ:INCR)

innateimmuno.com

"Investors Fact Sheet". Innate Immunotherapeutics Limited. North Melboure. nd. Retrieved August 8, 2018.

innateimmunotherapeutics.com

"MIS416", Innate Immunotherapeutics, archived from the original on August 14, 2015, retrieved June 14, 2015

multiplesclerosisnewstoday.com

Semedo, Daniela (April 15, 2016). "Innate Immunotherapeutics Fully Enrolls Phase 2 Study of Drug Candidate to Treat SPMS". Multiple Sclerosis News Today. Retrieved August 8, 2018.
Dutt, Streetama (July 17, 2017). "MIS416 for Secondary Progressive Multiple Sclerosis". Multiple Sclerosis News Today via BioNews Services. Dallas, Texas. Retrieved August 8, 2018.

nasdaq.com

"Innate Immunotherapeutics Ltd Stock Chart (INNMF)", NASDAQ, January 24, 2017, retrieved January 24, 2017

nih.gov

pubmed.ncbi.nlm.nih.gov

Shirani, Afsaneh; Okuda, Darin T.; Stüve1, Olaf (January 2016). "Therapeutic Advances and Future Prospects in Progressive Forms of Multiple Sclerosis". Neurotherapeutics. 3 (1): 58–69. doi:10.1007/s13311-015-0409-z. PMC 4720678. PMID 26729332.{{cite journal}}: CS1 maint: numeric names: authors list (link)
Madeleine, White; Webster, Gill; O'Sullivan, David; Stone, Sarrabeth; La Flamme, Anne Camille (January 31, 2014). "Targeting innate receptors with MIS416 reshapes Th responses and suppresses CNS disease in a mouse model of multiple sclerosis". PLOS ONE. 9 (1): e87712. Bibcode:2014PLoSO...987712W. doi:10.1371/journal.pone.0087712. PMC 3909208. PMID 24498172. [PMC free article] [PubMed] [Cross Ref]
Girvan RC, Knight DA, O'Loughlin CJ, Hayman CM, Hermans IF, Webster GA (January 10, 2011). "MIS416, a non-toxic microparticle adjuvant derived from Propionibacterium acnes comprising immunostimulatory muramyl dipeptide and bacterial DNA promotes cross-priming and Th1 immunity". Vaccine. 29 (3): 545–57. doi:10.1016/j.vaccine.2010.10.040. PMID 21034827.
Luckey, Alison M; Anderson, Tim; Silverman, Michael H; Webster, Gill (January 2015). "Safety, tolerability and pharmacodynamics of a novel immunomodulator, MIS416, in patients with chronic progressive multiple sclerosis". Multiple Sclerosis Journal: Experimental, Translational and Clinical. 1: 2055217315583385. doi:10.1177/2055217315583385. PMC 5433401. PMID 28607691.

ncbi.nlm.nih.gov

Shirani, Afsaneh; Okuda, Darin T.; Stüve1, Olaf (January 2016). "Therapeutic Advances and Future Prospects in Progressive Forms of Multiple Sclerosis". Neurotherapeutics. 3 (1): 58–69. doi:10.1007/s13311-015-0409-z. PMC 4720678. PMID 26729332.{{cite journal}}: CS1 maint: numeric names: authors list (link)
Madeleine, White; Webster, Gill; O'Sullivan, David; Stone, Sarrabeth; La Flamme, Anne Camille (January 31, 2014). "Targeting innate receptors with MIS416 reshapes Th responses and suppresses CNS disease in a mouse model of multiple sclerosis". PLOS ONE. 9 (1): e87712. Bibcode:2014PLoSO...987712W. doi:10.1371/journal.pone.0087712. PMC 3909208. PMID 24498172. [PMC free article] [PubMed] [Cross Ref]
Luckey, Alison M; Anderson, Tim; Silverman, Michael H; Webster, Gill (January 2015). "Safety, tolerability and pharmacodynamics of a novel immunomodulator, MIS416, in patients with chronic progressive multiple sclerosis". Multiple Sclerosis Journal: Experimental, Translational and Clinical. 1: 2055217315583385. doi:10.1177/2055217315583385. PMC 5433401. PMID 28607691.

nyti.ms

Katie Thomas (January 24, 2017), "Australian Drug Maker Has Low Profile but Powerful Backers in Washington", The New York Times, retrieved January 24, 2017

nytimes.com

Kaplan, Thomas; Rappeport, Alan; Huetteman, Emmarie (January 24, 2017). "Trump's Health Nominee Defends Stock Deals as 'Ethical, Above Board, Legal and Transparent'". New York Times. Retrieved January 24, 2017.
Feuer, Alan; Goldmacher, Shane (August 8, 2018). "New York Congressman Chris Collins Is Charged With Insider Trading". The New York Times. Retrieved August 8, 2018.

thehill.com

Wong, Scott (June 8, 2017). "Exclusive: GOP lawmaker talked stocks with colleagues". Retrieved June 8, 2017. The Buffalo News reported that many in the [Buffalo]'s business elite had bought stock in the drug company after hearing from Collins...Collins first invested in Innate Immunotherapeutics, which has developed a drug to fight advanced multiple sclerosis, about 15 years ago. He said he's raised money for the company during tough times and has earned a spot on its board of directors...[In August 2016, Collins] purchased an additional 4 million shares. On [January 27, 2017] the stock hit an all-time high of $1.83 per share, but it was trading at 74 cents per share on [May 7, 2017].

web.archive.org

"MIS416", Innate Immunotherapeutics, archived from the original on August 14, 2015, retrieved June 14, 2015

wgrz.com

"Son of former Congressman Chris Collins sentenced to 5 years of probation". WGRZ. 23 January 2020. Retrieved 2020-01-24.

worldcat.org

search.worldcat.org

Tau, Byron (October 12, 2017). "Congressional Ethics Office Says New York Republican May Have Violated Law". Wall Street Journal. ISSN 0099-9660. Retrieved August 8, 2018.

wsj.com

Tau, Byron (October 12, 2017). "Congressional Ethics Office Says New York Republican May Have Violated Law". Wall Street Journal. ISSN 0099-9660. Retrieved August 8, 2018.